Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIDE: Envudeucitinib in plaque psoriasis
NCT05600036Phase 2Completed
- Sponsor
- Alumis Inc.
- Start
- Sep 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of envudeucitinib in plaque psoriasis, sponsored by Alumis Inc.. Started Sep 2022; status: completed.
02
Drugs
envudeucitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05600036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05600036.